Printer Friendly

MGI PHARMA EXPANDS PRODUCT PORTFOLIO WITH POTENTIAL CHEMOTHERAPY PRODUCTS; PRODUCTS HAVE LONG TERM FOCUS

 MINNEAPOLIS, Jan. 14 /PRNewswire/ -- MGI Pharma, Inc. (NASDAQ: MOGN) a speciality pharmaceutical company, has acquired the rights to several United States and international patents for a number of new chemotherapy products. All are still in the early stages of development, but have the potential to be developed into meaningful cancer treatments.
 The patents cover three different classes of cyclophosphamide- related agents (cyclophosphamide analogs, aldophosphamide derivatives, and phosphoramidates) and phosphoramidate analogs of fluorodeoxyuridine monophosphate (PF-dUMP). If these compounds can be successfully developed, they could prove to be effective in treating a variety of cancers, including leukemia and cancers of the gastrointestinal tract, head and neck, breast and lung.
 These compounds were acquired from the University of Rochester and the Research Corporation Technologies, an organization that helps universities place their technologies with companies capable of developing and marketing products. The initial development of all the compounds was conducted at the University of Rochester, Rochester, N.Y.
 Charles C. Muscoplat, MGI Pharma's executive vice president of new business development, stated "As we have mentioned in the past, we have been aggressively looking for new and promising products to bring into our development portfolio. We are happy to have acquired these compounds and look forward to developing them into new pharmaceuticals. While they are all early stage development products with no near term revenue potential, they do help to build the long term oncology-focus of the company."
 Cyclophosphamide-related Agents
 Cyclophosphamide is one of the most widely used chemotherapeutic agents against a variety of cancers. While it works relatively well by interfering with the ability of cancer cells to reproduce, it does have some weaknesses. First, cyclophosphamide must be metabolized in the liver to produce the activated metabolites that are toxic to the cancer cells. Unfortunately, certain cyclophosphamide metabolites are also toxic to the urinary bladder and bone marrow and do not contribute any anti-tumor activity. After repeated use, cancer cells can build up a resistance to cyclophosphamide making it less effective.
 MGI Pharma's new compounds, which are chemical derivatives of cyclophosphamide, appear to have several desirable attributes. The new compounds are directly active, meaning they don't need to be metabolized in the liver to acquire antitumor activity and thus are not toxic to the bladder. Laboratory studies have shown the compounds to be effective against tumors that are resistant to the current form of cyclophosphamide. Additionally, these products have varying degrees of lipid solubility making them potentially more selective in their distribution throughout the body, which may preferentially improve the antitumor activity for certain tumor types. Some of these new agents have even shown the potential to treat tumors under oxygen deficient conditions, which has been difficult to accomplish in the past.
 The new cyclophosphamide-related agents have been tested in the laboratory with promising results and have been used in some animal models. However, they are still very early in the development cycle and will require considerable additional animal testing before being submitted to the full battery of human clinical tests. The timelines for the development of these agents has not yet been determined.
 Phosphoramidate Flourodeoxyuridine Monophosphate Analogs
 Phosphoramidate flourodeoxyuridine monophosphate analogs (PF-dUMP) are anti-metabolites that work by interfering with tumor cells' metabolic machinery and thereby inhibit their ability to grow. They are similar to the well known and widely used anti-tumor agent 5-FU, however, they appear to have advantages in potency and selectivity over 5-FU.
 5-FU has been used for many years to treat a variety of cancers, most specifically tumors of the breast and gastrointestinal (GI) tract. Its use has been based on its potential to inhibit thymidylate synthase. 5-FU must be metabolized in the cells to produce another substance, which in turn produces the desired anti-tumor effect. In this case, 5-FU is enzymatically changed in the cell to the toxic metabolite 5-FdUMP, which is the active inhibitor of thymidylate synthase. Unfortunately, some cells do not have the ability to activate 5-FU into its active metabolite, which limits the drug's ability to kill cancer cells. MGI Pharma's new PF-dUMPs have the advantage of delivering the active metabolite directly to the cell without relying on any enzymatic changes to produce the desired anti-tumor effect.
 The new PF-dUMPs have so far only been tested in the laboratory. The results of these tests have been encouraging in that they show the new PF-dUMPs are better inhibitors of thymidylate synthase and have a higher affinity to kill certain cancer cells than 5-FU. The PF-dUMP analogs may be developed to treat cancers of the GI tract, head and neck, and leukemia. The timeline for this development has not yet been determined.
 -0- 1/14/93
 /CONTACT: Lori Weiman of MGI Pharma, 612-939-4666/
 (MOGN)


CO: MGI Pharma, Inc. ST: Minnesota IN: MTC SU: PDT

DS -- MN003 -- 4786 01/14/93 10:25 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 14, 1993
Words:795
Previous Article:ATTN AVECA ANNOUNCES NEW CHAIRMAN OF BOARD AND SIGNING OF MAJOR TRUCKING COMPANIES LOOKING FOR QUALIFIED DRIVERS
Next Article:MGI PHARMA ACQUIRES RIGHTS TO POTENTIAL NEW DRUG FOR CHRONIC DRY MOUTH; PRODUCT IN EARLY STAGE OF DEVELOPMENT
Topics:


Related Articles
MGI PHARMA ACQUIRES NEW CRITICAL CARE DRUG; MGI 330 COULD IMPROVE DIAGNOSIS OF HEART DISEASE AND RECOVERY FROM ISCHEMIA
MGI PHARMA REPORTS FIRST QUARTER 1993 RESULTS
MGI PHARMA ACQUIRES EARLY STAGE COMPOUNDS WITH POTENTIAL TO BECOME BREAKTHROUGH ANTI-CANCER TREATMENT
MGI PHARMA's SALAGEN(R) TABLETS CLEARED FOR MARKETING BY FDA; PRODUCT TREATS RADIATION-INDUCED DRY MOUTH IN HEAD AND NECK CANCER PATIENTS
MGI PHARMA, INC. GRANTS AN OPTION FOR JAPANESE RIGHTS TO CANCER COMPOUNDS AND SELLS COMMON STOCK TO DAINIPPON PHARMACEUTICAL CO., LTD.
MGI PHARMA, INC. APPOINTS NEW VICE PRESIDENT OF SALES AND MARKETING; COMMENTS ON SECOND QUARTER GROWTH
NATIONAL CANCER INSTITUTE VOTES FOR FUNDING OF CLINICAL TRIALS ON MGI PHARMA ACYLFULVENE COMPOUND
MGI Pharma Announces 1996 and Fourth Quarter Results; 1996 Product Sales Increase 40 Percent Over 1995
MGI PHARMA Purchasing Hexalen(R) From MedImmune for Ovarian Cancer.
MGI PHARMA EXPECTS $78 MILLION TOTAL REVENUE FOR FIRST QTR.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters